Dr. Herriot Tabuteau’s story is the kind of American success that should make every patriot proud: an immigrant from Haiti who became a Yale-educated physician and then built a medicines company from a small office into a global competitor. He didn’t wait for permission from Washington or seek a government bailout — he rolled up his sleeves, used his medical training and business smarts, and created real jobs and life-changing treatments. That kind of grit and self-reliance is exactly what built this country.
Axsome Therapeutics today sits in the roughly six billion dollar valuation range and is standing squarely in the arena of neuroscience, with multiple marketed medicines and a deep pipeline aimed at mind-robbing disorders. The company now lists three drugs on the market and as many as five late-stage programs in development, positioning itself to serve millions of Americans battling depression, Alzheimer’s agitation, sleep disorders and more. This is the private sector delivering where bureaucracy and political hand-wringing too often fail.
The company’s commercial portfolio includes AUVELITY for major depression and SUNOSI for excessive daytime sleepiness, and the firm recently celebrated an FDA approval and launch for SYMBRAVO, a new oral migraine therapy that promises faster relief for sufferers. Investors and patients notice when a company moves from paper promises to approved pills, and the FDA nod for SYMBRAVO is a textbook example of science and enterprise translating into real-world help. That kind of progress should be cheered, not demonized by those who reflexively distrust business.
Axsome’s results underscore that innovation can pay off even before a company turns profit: the business reported roughly half a billion dollars in revenue over the trailing twelve months, with rapid top-line growth as it scales commercialization. Yes, they reported a net loss as they invest in development and launch activities, but that is how drug companies build pipelines that save lives — you invest now so patients get better options later. Private investors and markets, not Washington decrees, should reward winners who take that risk.
What’s coming next is what keeps the free market engine running: late-stage filings and potential new approvals. Axsome has signaled regulatory filings for AXS-05 in Alzheimer’s agitation and has advanced AXS-12 through convincing late-stage narcolepsy data, steps that could widen treatment choices for people suffering from brutal brain disorders. This is the payoff for years of research and bold clinical bets, and it underscores why strong intellectual property and capital markets matter for American medicine.
If you’re a conservative who still believes in American exceptionalism, this company’s rise is a reminder that entrepreneurship and competition — not bigger government — produce breakthroughs. We should be making it easier, not harder, for founders and scientists to build companies like this one by cutting needless red tape, protecting patents, and fostering capital formation. When we unleash talent and investment, we get cures and cures create jobs; that’s a pro-worker, pro-family, pro-freedom agenda.
So let’s celebrate the kind of private-sector boldness that Dr. Tabuteau represents and demand policies that let more Americans do the same. Support entrepreneurs, defend free markets, and remember that when Americans are free to innovate, the country wins and everyday families get the medicines they need.
